Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-week...

Descripción completa

Detalles Bibliográficos
Autores principales: BOESJES, Celeste M., KAMPHUIS, Esmé, ZUITHOFF, Nicolaas P. A., BAKKER, Daphne S., LOMAN, Laura, SPEKHORST, Lotte S., HAECK, Inge, KAMSTEEG, Marijke, VAN LYNDEN-VAN NES, Anneke M. T., GARRITSEN, Floor M., POLITIEK, Klaziena, OLDHOFF, Marja, DE GRAAF, Marlies, SCHUTTELAAR, Marie L. A., DE BRUIN-WELLER, Marjolein S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811281/
https://www.ncbi.nlm.nih.gov/pubmed/36420885
http://dx.doi.org/10.2340/actadv.v102.3978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811281/
https://www.ncbi.nlm.nih.gov/pubmed/36420885
http://dx.doi.org/10.2340/actadv.v102.3978

Ejemplares similares